Works by Hamid, Omid

Results: 57
    1
    2
    3
    4

    Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

    Published in:
    2017
    By:
    • Sekulic, Aleksandar;
    • Migden, Michael R.;
    • Basset-Seguin, Nicole;
    • Garbe, Claus;
    • Gesierich, Anja;
    • Lao, Christopher D.;
    • Miller, Chris;
    • Mortier, Laurent;
    • Murrell, Dedee F.;
    • Hamid, Omid;
    • Quevedo, Jorge F.;
    • Hou, Jeannie;
    • McKenna, Edward;
    • Dimier, Natalie;
    • Williams, Sarah;
    • Schadendorf, Dirk;
    • Hauschild, Axel;
    • ERIVANCE BCC Investigators
    Publication type:
    journal article
    5
    6
    7

    Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 3, p. 467, doi. 10.1007/s00280-013-2372-x
    By:
    • Mahadevan, Daruka;
    • Sutton, Gregory;
    • Arteta-Bulos, Rafael;
    • Bowden, Chris;
    • Miller, Paul;
    • Swart, Rachel;
    • Walker, Mark;
    • Haluska, Paul;
    • Munster, Pamela;
    • Marshall, John;
    • Hamid, Omid;
    • Kurzrock, Razelle
    Publication type:
    Article
    8

    Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).

    Published in:
    Neuro-Oncology, 2021, v. 23, n. 11, p. 1961, doi. 10.1093/neuonc/noab094
    By:
    • Tawbi, Hussein A;
    • Forsyth, Peter A;
    • Hodi, F Stephen;
    • Lao, Christopher D;
    • Moschos, Stergios J;
    • Hamid, Omid;
    • Atkins, Michael B;
    • Lewis, Karl;
    • Thomas, Reena P;
    • Glaspy, John A;
    • Jang, Sekwon;
    • Algazi, Alain P;
    • Khushalani, Nikhil I;
    • Postow, Michael A;
    • Pavlick, Anna C;
    • Ernstoff, Marc S;
    • Reardon, David A;
    • Puzanov, Igor;
    • Kudchadkar, Ragini R;
    • Tarhini, Ahmad A
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15

    Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.

    Published in:
    Pigment Cell & Melanoma Research, 2025, v. 38, n. 1, p. 1, doi. 10.1111/pcmr.13205
    By:
    • Seedor, Rino S.;
    • Aplin, Andrew E.;
    • Bertolotto, Corine;
    • Carvajal, Richard D.;
    • Deacon, Nigel;
    • Doble, Katie;
    • Hamid, Omid;
    • Haq, Rizwan;
    • Kadosh, Miriam;
    • Khan, Shaheer;
    • Kraska, Jacqueline;
    • Lutzky, Jose;
    • McKean, Meredith;
    • Montazeri, Kamaneh;
    • Moser, Justin;
    • Onken, Michael;
    • Orloff, Marlana;
    • Sacco, Joseph J.;
    • Smalley, Keiran;
    • Selig, Sara M.
    Publication type:
    Article
    16

    Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022).

    Published in:
    Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04117-3
    By:
    • Ascierto, Paolo A.;
    • Avallone, Antonio;
    • Bifulco, Carlo;
    • Bracarda, Sergio;
    • Brody, Joshua D.;
    • Emens, Leisha A.;
    • Ferris, Robert L.;
    • Formenti, Silvia C.;
    • Hamid, Omid;
    • Johnson, Douglas B.;
    • Kirchhoff, Tomas;
    • Klebanoff, Christopher A.;
    • Lesinski, Gregory B.;
    • Monette, Anne;
    • Neyns, Bart;
    • Odunsi, Kunle;
    • Paulos, Chrystal M.;
    • Powell Jr., Daniel J.;
    • Rezvani, Katayoun;
    • Segal, Brahm H.
    Publication type:
    Article
    17

    The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022.

    Published in:
    Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04100-y
    By:
    • Ascierto, Paolo A.;
    • Blank, Christian;
    • Eggermont, Alexander M.;
    • Garbe, Claus;
    • Gershenwald, Jeffrey E.;
    • Hamid, Omid;
    • Hauschild, Axel;
    • Luke, Jason J.;
    • Mehnert, Janice M.;
    • Sosman, Jeffrey A.;
    • Tawbi, Hussein A.;
    • Mandalà, Mario;
    • Testori, Alessandro;
    • Caracò, Corrado;
    • Osman, Iman;
    • Puzanov, Igor
    Publication type:
    Article
    18

    Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

    Published in:
    2019
    By:
    • Sekulic, Aleksandar;
    • Migden, Michael R.;
    • Basset-Seguin, Nicole;
    • Garbe, Claus;
    • Gesierich, Anja;
    • Lao, Christopher D.;
    • Miller, Chris;
    • Mortier, Laurent;
    • Murrell, Dedee F.;
    • Hamid, Omid;
    • Quevedo, Jorge F.;
    • Hou, Jeannie;
    • McKenna, Edward;
    • Dimier, Natalie;
    • Williams, Sarah;
    • Schadendorf, Dirk;
    • Hauschild, Axel;
    • ERIVANCE BCC Investigators
    Publication type:
    journal article
    19
    20

    LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 4, p. 1057, doi. 10.1007/s10637-021-01084-8
    By:
    • Dowlati, Afshin;
    • Harvey, R. Donald;
    • Carvajal, Richard D.;
    • Hamid, Omid;
    • Klempner, Samuel J.;
    • Kauh, John Sae Wook;
    • Peterson, Daniel A.;
    • Yu, Danni;
    • Chapman, Sonya C.;
    • Szpurka, Anna M.;
    • Carlsen, Michelle;
    • Quinlan, Tonya;
    • Wesolowski, Robert
    Publication type:
    Article
    21

    Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 3, p. 844, doi. 10.1007/s10637-019-00832-1
    By:
    • Sandhu, Shahneen;
    • McNeil, Catriona M.;
    • LoRusso, Patricia;
    • Patel, Manish R.;
    • Kabbarah, Omar;
    • Li, Chunze;
    • Sanabria, Sandra;
    • Flanagan, W. Michael;
    • Yeh, Ru-Fang;
    • Brunstein, Flavia;
    • Nazzal, Denise;
    • Hicks, Rodney;
    • Lemahieu, Vanessa;
    • Meng, Raymond;
    • Hamid, Omid;
    • Infante, Jeffrey R.
    Publication type:
    Article
    22
    23
    24
    25

    Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

    Published in:
    Cancer Immunology, Immunotherapy, 2019, v. 68, n. 4, p. 609, doi. 10.1007/s00262-018-02295-4
    By:
    • D'Angelo, Sandra P.;
    • Hunger, Matthias;
    • Brohl, Andrew S.;
    • Nghiem, Paul;
    • Bhatia, Shailender;
    • Hamid, Omid;
    • Mehnert, Janice M.;
    • Terheyden, Patrick;
    • Shih, Kent C.;
    • Brownell, Isaac;
    • Lebbé, Céleste;
    • Lewis, Karl D.;
    • Linette, Gerald P.;
    • Milella, Michele;
    • Schlichting, Michael;
    • Hennessy, Meliessa H.;
    • Bharmal, Murtuza
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33
    34

    A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

    Published in:
    Cancer (0008543X), 2014, v. 120, n. 13, p. 2016, doi. 10.1002/cncr.28635
    By:
    • Hamid, Omid;
    • Ilaria, Robert;
    • Garbe, Claus;
    • Wolter, Pascal;
    • Maio, Michele;
    • Hutson, Thomas E.;
    • Arance, Ana;
    • Lorigan, Paul;
    • Lee, Jeeyun;
    • Hauschild, Axel;
    • Mohr, Peter;
    • Hahka‐Kemppinen, Marjo;
    • Kaiser, Christopher;
    • Turner, P. Kellie;
    • Conti, Ilaria;
    • Grob, Jean‐Jacques
    Publication type:
    Article
    35

    Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).

    Published in:
    2019
    By:
    • Ascierto, Paolo A.;
    • Agarwala, Sanjiv S.;
    • Botti, Gerardo;
    • Budillon, Alfredo;
    • Davies, Michael A.;
    • Dummer, Reinhard;
    • Ernstoff, Marc;
    • Ferrone, Soldano;
    • Formenti, Silvia;
    • Gajewski, Thomas F.;
    • Garbe, Claus;
    • Hamid, Omid;
    • Lo, Roger S.;
    • Luke, Jason J.;
    • Michielin, Oliver;
    • Palmieri, Giuseppe;
    • Zitvogel, Laurence;
    • Marincola, Francesco M.;
    • Masucci, Giuseppe;
    • Caracò, Corrado
    Publication type:
    journal article
    36
    37
    38
    39
    40
    41
    42
    43

    Programmed Death 1 Immune Checkpoint Inhibitors.

    Published in:
    Clinical Advances in Hematology & Oncology, 2015, v. 13, n. 12, p. 858
    By:
    • Trivedi, Meghna S.;
    • Hoffner, Brianna;
    • Winkelmann, Jennifer L.;
    • Abbott, Maura E.;
    • Hamid, Omid;
    • Carvajal, Richard D.
    Publication type:
    Article
    44
    45
    46

    POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.

    Published in:
    Neuro-Oncology Advances, 2024, v. 6, n. 1, p. 1, doi. 10.1093/noajnl/vdae033
    By:
    • Menzies, Alexander M;
    • Long, Georgina V;
    • Kohn, Amiee;
    • Tawbi, Hussein;
    • Weber, Jeffrey;
    • Flaherty, Keith;
    • McArthur, Grant A;
    • Ascierto, Paolo A;
    • Pfluger, Yanina;
    • Lewis, Karl;
    • Tsai, Katy K;
    • Hamid, Omid;
    • Prenen, Hans;
    • Fein, Luis;
    • Wang, Erjian;
    • Guenzel, Carolin;
    • Zhang, Fan;
    • Kleha, Joseph F;
    • Pietro, Alessandra di;
    • Davies, Michael A
    Publication type:
    Article
    47
    48

    The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.

    Published in:
    2020
    By:
    • Ascierto, Paolo A.;
    • Agarwala, Sanjiv S.;
    • Eggermont, Alexander;
    • Gershenwald, Jeffrey E.;
    • Grob, Jean-Jacques;
    • Hamid, Omid;
    • Michielin, Olivier;
    • Postow, Michael;
    • Puzanov, Igor;
    • Zarour, Hassane M.;
    • Caracò, Corrado;
    • Testori, Alessandro
    Publication type:
    journal article
    49
    50